Final Stage 2 Results of the CLL11 Trial
Jennifer Brown, MD, PhD, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
Clinical Pearls
Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses final stage 2 results of the CLL11 trial at the 2013 American Society of Hematology (ASH) Meeting.
- The CLL11 study provided the basis for the approval of GA101 (obinutuzumab)
- GA101 has a different mechanism than rituximab or ofatumumab in that it confers increased direct cell death
- GA101 + chlorambucil compared with chlorambucil alone now has demonstrated a statistically significant improvement in overall survival
- In the direct comparison, GA101 + chlorambucil demonstrated an improvement in progression-free survival compared with rituximab + chlorambucil (27 months vs 16 months)
- GA101 + chlorambucil also has demonstrated a higher complete remission rate and MRD negativity rate
<<<
Selection of Next-Gen BTK in CLL Limited By Lack of Direct Comparison
February 4th 2025During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK inhibitor therapies acalabrutinib and zanubrutinib in patients with chronic lymphocytic leukemia who received 1 prior line of therapy in the second article of a 2-part series.
Read More
